PHILADELPHIA, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of Immunomedics, Inc. ("Immunomedics") (NasdaqGM:IMMU).
You may obtain additional information or assist in the investigation by contacting John Kehoe, Esq., at (215) 792-6676, Ext. 801, jkehoe@kehoelawfirm.com, info@kehoelawfirm.com.
The investigation concerns whether certain of the officers or directors of Immunomedics may have violated federal securities laws. Specifically, on December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” FDAnews.com reported, in part, that “[t]he FDA cited Immunomedics for a host of violations—including its handling of a data integrity breach—observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article further reported that the data breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”
Following publication of this article, Immunomedics’ stock price fell sharply on December 20, 2018, damaging investors.
If you are a stockholder of Immunomedics, you are encouraged to contact John Kehoe, Esq., (215) 792-6676, Ext. 801, jkehoe@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about Kehoe Law Firm’s investigation and your potential legal claims.
This press release may be considered Attorney Advertising in some jurisdictions, under the applicable law and ethical rules.
Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have been lead or co-lead counsel in cases that have recovered more than $10 billion dollars on behalf of institutional and individual investors.